VTGN – BioTuesdays

Features

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Markets

WB ups VistaGen Therapeutics to OP; fair value estimate $9

William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...

January 4, 2021

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Developments

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...

January 30, 2020

Markets

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

William Blair downgraded VistaGen Therapeutics (NASDAQ:VTGN) to “market perform” after the Phase 2 ELEVATE study of AV-101 for the adjunctive treatment of major depressive disorder (MDD) failed to meet its primary...

November 14, 2019

Markets

WB starts VistaGen Therapeutics at OP; fair value estimate $7

William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing...

August 28, 2019

Tag - VTGN

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

WB ups VistaGen Therapeutics to OP; fair value estimate $9

VistaGen reports positive results from Phase 2a major depressive disorder study

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter